We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Experimental Vaccine Protects Monkeys Against CCHFV

Experimental Vaccine Protects Monkeys Against CCHFV

Experimental Vaccine Protects Monkeys Against CCHFV

Experimental Vaccine Protects Monkeys Against CCHFV

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Experimental Vaccine Protects Monkeys Against CCHFV"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

An experimental vaccine developed in Europe to prevent infection by Crimean-Congo hemorrhagic fever virus (CCHFV) has protected cynomolgus macaques in a new collaborative study from National Institutes of Health scientists. The animals received the DNA-based candidate vaccine through intramuscular injection immediately followed by electroporation—a process in development for human vaccines that helps cells absorb DNA. The study, published in Nature Microbiology, comes about three years after the same research group developed the macaque model for CCHFV. No specific treatments or vaccines for CCHFV exist.

Crimean-Congo hemorrhagic fever, first described in 1944, is spread primarily by the bite of Hyalomma ticks found in the Middle East, Asia, Africa and parts of Europe. The virus also can be transmitted to people by direct contact with infected fluids or tissue from people or certain livestock species. CCHFV infects up to 15,000 people annually, according to the World Health Organization. About 1 in 8 of those who are infected develop severe disease, which leads to about 500 deaths each year. CCHFV also is considered a possible agent of bioterrorism.

Scientists from NIH’s National Institute of Allergy and Infectious Diseases (NIAID) in Hamilton, Montana, tested the candidate vaccine on six cynomolgus macaques, each of which received three inoculations, followed by electroporation, at three-week intervals. No animals experienced significant adverse reactions upon vaccination. Through regular blood tests, the researchers confirmed that the candidate vaccine generated protective antibodies against the virus. They then infected the vaccinated animals with CCHFV and monitored them for clinical signs for six days, after which they looked for virus in their organs. Six control animals infected with CCHFV but not given the experimental vaccine showed signs of disease throughout the study. The vaccinated animals did not. Their blood tests remained largely unchanged with no indication of progressive virus infection and no virus shedding. Virus was nearly undetectable in their liver, kidneys, lungs and adrenal glands, all targets of CCHFV.

Collaborators at the Karolinska Institute in Sweden developed the candidate vaccine with colleagues from the Public Health Agency of Sweden, the National Veterinary Institute of Sweden, the Justus Liebig University in Germany and NIAID’s Rocky Mountain Laboratories in Montana. The candidate vaccine uses two proteins from CCHFV to generate protection.

The researchers next plan to study if the vaccine candidate is effective with fewer than three doses and whether it offers long-term protection. They also plan to continue evaluating the use of electroporation to make vaccination more effective.

Reference: Hawman DW, Ahlén G, Appelberg KS, et al. A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a Cynomolgus macaque model. Nat Microbiol. 2020. doi:10.1038/s41564-020-00815-6

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.